Transgenic inhibition of interleukin-6 trans-signaling does not prevent skeletal pathologies in mucolipidosis type II mice.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
11 02 2021
11 02 2021
Historique:
received:
25
09
2020
accepted:
25
01
2021
entrez:
12
2
2021
pubmed:
13
2
2021
medline:
16
11
2021
Statut:
epublish
Résumé
Severe skeletal alterations are common symptoms in patients with mucolipidosis type II (MLII), a rare lysosomal storage disorder of childhood. We have previously reported that progressive bone loss in a mouse model for MLII is caused by an increased number of bone-resorbing osteoclasts, which is accompanied by elevated expression of the cytokine interleukin-6 (IL-6) in the bone microenvironment. In the present study we addressed the question, if pharmacological blockade of IL-6 can prevent the low bone mass phenotype of MLII mice. Since the cellular IL-6 response can be mediated by either the membrane-bound (classic signaling) or the soluble IL-6 receptor (trans-signaling), we first performed cell culture assays and found that both pathways can increase osteoclastogenesis. We then crossed MLII mice with transgenic mice expressing the recombinant soluble fusion protein sgp130Fc, which represents a natural inhibitor of IL-6 trans-signaling. By undecalcified histology and bone-specific histomorphometry we found that high circulating sgp130Fc levels do not affect skeletal growth or remodeling in wild-type mice. Most importantly, blockade of IL-6 trans-signaling did neither reduce osteoclastogenesis, nor increase bone mass in MLII mice. Therefore, our data clearly demonstrate that the bone phenotype of MLII mice cannot be corrected by blocking the IL-6 trans-signaling.
Identifiants
pubmed: 33574442
doi: 10.1038/s41598-021-82802-3
pii: 10.1038/s41598-021-82802-3
pmc: PMC7878873
doi:
Substances chimiques
Interleukin-6
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3556Subventions
Organisme : Versus Arthritis
ID : 22043
Pays : United Kingdom
Références
Ducy, P., Schinke, T. & Karsenty, G. The osteoblast: a sophisticated fibroblast under central surveillance. Science 289, 1501–1504 (2000).
pubmed: 10968779
doi: 10.1126/science.289.5484.1501
Cappariello, A., Maurizi, A., Veeriah, V. & Teti, A. The Great Beauty of the osteoclast. Arch. Biochem. Biophys. 558, 70–78 (2014).
pubmed: 24976175
doi: 10.1016/j.abb.2014.06.017
Dallas, S. L., Prideaux, M. & Bonewald, L. F. The osteocyte: an endocrine cell … and more. Endocr Rev 34, 658–690 (2013).
pubmed: 23612223
pmcid: 3785641
doi: 10.1210/er.2012-1026
Yasuda, H. et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 95, 3597–3602 (1998).
pubmed: 9520411
doi: 10.1073/pnas.95.7.3597
pmcid: 19881
Boyle, W. J., Simonet, W. S. & Lacey, D. L. Osteoclast differentiation and activation. Nature 423, 337–342 (2003).
pubmed: 12748652
doi: 10.1038/nature01658
Blair, H. C., Robinson, L. J. & Zaidi, M. Osteoclast signalling pathways. Biochem. Biophys. Res. Commun. 328, 728–738 (2005).
pubmed: 15694407
doi: 10.1016/j.bbrc.2004.11.077
Kotake, S. et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J. Bone Miner. Res. 11, 88–95 (1996).
pubmed: 8770701
doi: 10.1002/jbmr.5650110113
Kurihara, N., Bertolini, D., Suda, T., Akiyama, Y. & Roodman, G. D. IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release. J. Immunol. 144, 4226–4230 (1990).
pubmed: 2341718
doi: 10.4049/jimmunol.144.11.4226
Kudo, O. et al. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone 32, 1–7 (2003).
pubmed: 12584029
doi: 10.1016/S8756-3282(02)00915-8
Feng, W. et al. Combination of IL-6 and sIL-6R differentially regulate varying levels of RANKL-induced osteoclastogenesis through NF-κB, ERK and JNK signaling pathways. Sci. Rep. 7, 41411 (2017).
pubmed: 28128332
pmcid: 5269740
doi: 10.1038/srep41411
Clowes, J. A., Riggs, B. L. & Khosla, S. The role of the immune system in the pathophysiology of osteoporosis. Immunol. Rev. 208, 207–227 (2005).
pubmed: 16313351
doi: 10.1111/j.0105-2896.2005.00334.x
Scheidt-Nave, C. et al. Serum interleukin 6 is a major predictor of bone loss in women specific to the first decade past menopause. J. Clin. Endocrinol. Metab. 86, 2032–2042 (2001).
pubmed: 11344203
Teramachi, J. et al. Increased IL-6 expression in osteoclasts is necessary but not sufficient for the development of Paget’s disease of bone. J. Bone Miner. Res. 29, 1456–1465 (2014).
pubmed: 24339057
doi: 10.1002/jbmr.2158
Scheller, J., Garbers, C. & Rose-John, S. Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities. Semin. Immunol. 26, 2–12 (2014).
pubmed: 24325804
doi: 10.1016/j.smim.2013.11.002
Schaper, F. & Rose-John, S. Interleukin-6: Biology, signaling and strategies of blockade. Cytokine Growth Factor Rev. 26, 475–487 (2015).
pubmed: 26189695
doi: 10.1016/j.cytogfr.2015.07.004
Tamura, T. et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc. Natl. Acad. Sci. USA 90, 11924–11928 (1993).
pubmed: 8265649
doi: 10.1073/pnas.90.24.11924
pmcid: 48097
Romas, E. et al. The role of gp130-mediated signals in osteoclast development: regulation of interleukin 11 production by osteoblasts and distribution of its receptor in bone marrow cultures. J. Exp. Med. 183, 2581–2591 (1996).
pubmed: 8676079
doi: 10.1084/jem.183.6.2581
Gao, Y. et al. Expression of IL-6 receptor and GP130 in mouse bone marrow cells during osteoclast differentiation. Bone 22, 487–493 (1998).
pubmed: 9600782
doi: 10.1016/S8756-3282(98)00040-4
Adebanjo, O. A. et al. Mode of action of interleukin-6 on mature osteoclasts. Novel interactions with extracellular Ca
pubmed: 9732294
pmcid: 2149353
doi: 10.1083/jcb.142.5.1347
Langub, M. C. Jr. et al. Bone resorption and mRNA expression of IL-6 and IL-6 receptor in patients with renal osteodystrophy. Kidney Int. 50, 515–520 (1996).
pubmed: 8840280
doi: 10.1038/ki.1996.343
Danks, L., Workman, S., Webster, D. & Horwood, N. J. Elevated cytokine production restores bone resorption by human Btk-deficient osteoclasts. J. Bone Miner. Res. 26, 182–192 (2011).
pubmed: 20715177
doi: 10.1002/jbmr.210
Udagawa, N. et al. Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors. J. Exp. Med. 182, 1461–1468 (1995).
pubmed: 7595216
doi: 10.1084/jem.182.5.1461
Sims, N. A. Cell-specific paracrine actions of IL-6 family cytokines from bone, marrow and muscle that control bone formation and resorption. Int. J. Biochem. Cell Biol. 79, 14–23 (2016).
pubmed: 27497989
doi: 10.1016/j.biocel.2016.08.003
Rose-John, S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int. J. Biol. Sci. 8, 1237–1247 (2012).
pubmed: 23136552
pmcid: 3491447
doi: 10.7150/ijbs.4989
Liu, X., Jones, G. W., Choy, E. H. & Jones, S. A. The biology behind interleukin-6 targeted interventions. Curr. Opin. Rheumatol. 28, 152–160 (2016).
pubmed: 26751841
doi: 10.1097/BOR.0000000000000255
Velho, R. V. et al. The lysosomal storage disorders mucolipidosis type II, type III alpha/beta and type III gamma: update on GNPTAB and GNPTG mutations. Hum. Mutat. 40, 842–864 (2019).
pubmed: 30882951
Marschner, K., Kollmann, K., Schweizer, M., Braulke, T. & Pohl, S. A key enzyme in the biogenesis of lysosomes is a protease that regulates cholesterol metabolism. Science 333, 87–90 (2011).
pubmed: 21719679
doi: 10.1126/science.1205677
Kollmann, K. et al. Mannose phosphorylation in health and disease. Eur. J. Cell Biol. 89, 117–123 (2010).
pubmed: 19945768
doi: 10.1016/j.ejcb.2009.10.008
Tiede, S. et al. Mucolipidosis II is caused by mutations in GNPTA encoding the alpha/beta GlcNAc-1-phosphotransferase. Nat. Med. 11, 1109–1112 (2005).
pubmed: 16200072
doi: 10.1038/nm1305
Kollmann, K. et al. Decreased bone formation and increased osteoclastogenesis cause bone loss in mucolipidosis II. EMBO Mol. Med. 5, 1871–1886 (2013).
pubmed: 24127423
pmcid: 3914524
doi: 10.1002/emmm.201302979
Schinke, T. et al. The protein tyrosine phosphatase Rptpzeta is expressed in differentiated osteoblasts and affects bone formation in mice. Bone 42, 524–534 (2008).
pubmed: 18178537
doi: 10.1016/j.bone.2007.11.009
Brylka, L. J. & Schinke, T. Chemokines in physiological and pathological bone remodeling. Front. Immunol. 10, 2182 (2019).
pubmed: 31572390
pmcid: 6753917
doi: 10.3389/fimmu.2019.02182
Pohl, S. et al. The lysosomal protein arylsulfatase B is a key enzyme involved in skeletal turnover. J. Bone Miner. Res. 33, 2186–2201 (2018).
pubmed: 30075049
doi: 10.1002/jbmr.3563
Fischer, M. et al. I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Nat Biotechnol 15, 142–145 (1997).
pubmed: 9035138
doi: 10.1038/nbt0297-142
Schmidt-Arras, D. & Rose-John, S. IL-6 pathway in the liver: from physiopathology to therapy. J. Hepatol. 64, 1403–1415 (2016).
pubmed: 26867490
doi: 10.1016/j.jhep.2016.02.004
Rabe, B. et al. Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood 111, 1021–1028 (2008).
pubmed: 17989316
doi: 10.1182/blood-2007-07-102137
McGregor, N. E. et al. IL-6 exhibits both cis- and trans-signaling in osteocytes and osteoblasts, but only trans-signaling promotes bone formation and osteoclastogenesis. J. Biol. Chem. 294, 7850–7863 (2019).
pubmed: 30923130
pmcid: 6514630
doi: 10.1074/jbc.RA119.008074
Karsenty, G. Transcriptional control of skeletogenesis. Annu. Rev. Genom. Hum. Genet. 9, 183–196 (2008).
doi: 10.1146/annurev.genom.9.081307.164437
De Benedetti, F. The impact of chronic inflammation on the growing skeleton: lessons from interleukin-6 transgenic mice. Horm. Res. 72(Suppl 1), 26–29 (2009).
pubmed: 19940492
De Benedetti, F. et al. Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system. Arthritis Rheumatol. 54, 3551–3563 (2006).
doi: 10.1002/art.22175
Kollmann, K. et al. Lysosomal dysfunction causes neurodegeneration in mucolipidosis II “knock-in” mice. Brain 135, 2661–2675 (2012).
pubmed: 22961545
pmcid: 3437033
doi: 10.1093/brain/aws209
Rachner, T. D., Khosla, S. & Hofbauer, L. C. Osteoporosis: now and the future. Lancet 377, 1276–1287 (2011).
pubmed: 21450337
pmcid: 3555696
doi: 10.1016/S0140-6736(10)62349-5
Poli, V. et al. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J. 13, 1189–1196 (1994).
pubmed: 8131749
pmcid: 394928
doi: 10.1002/j.1460-2075.1994.tb06368.x
Grano, M. et al. Rat hindlimb unloading by tail suspension reduces osteoblast differentiation, induces IL-6 secretion, and increases bone resorption in ex vivo cultures. Calcif. Tissue Int. 70, 176–185 (2002).
pubmed: 11907715
doi: 10.1007/s00223-001-2034-6
He, B. et al. Blockade of IL-6 alleviates bone loss induced by modeled microgravity in mice. Can. J. Physiol. Pharmacol. 98, 1–6 (2020).
doi: 10.1139/cjpp-2019-0632
Teufel, S. et al. Inhibition of bone remodeling in young mice by bisphosphonate displaces the plasma cell niche into the spleen. J. Immunol. 193, 223–233 (2014).
pubmed: 24899506
doi: 10.4049/jimmunol.1302713
Mackiewicz, A., Schooltink, H., Heinrich, P. C. & Rose-John, S. Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins. J. Immunol. 149, 2021–2027 (1992).
pubmed: 1381393
doi: 10.4049/jimmunol.149.6.2021
Schroers, A. et al. Dynamics of the gp130 cytokine complex: a model for assembly on the cellular membrane. Protein Sci. 14, 783–790 (2005).
pubmed: 15722452
pmcid: 2279283
doi: 10.1110/ps.041117105
Schulze, J. et al. Interleukin-33 is expressed in differentiated osteoblasts and blocks osteoclast formation from bone marrow precursor cells. J. Bone Miner. Res. 26, 704–717 (2011).
pubmed: 20939024
doi: 10.1002/jbmr.269
Kauffmann, A., Gentleman, R. & Huber, W. arrayQualityMetrics—a bioconductor package for quality assessment of microarray data. Bioinformatics 25, 415–416 (2009).
pubmed: 19106121
doi: 10.1093/bioinformatics/btn647
Smyth, G. K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3, Article3 (2004).
Leek, J. T. & Storey, J. D. Capturing heterogeneity in gene expression studies by surrogate variable analysis. PLoS Genet. 3, 1724–1735 (2007).
pubmed: 17907809
doi: 10.1371/journal.pgen.0030161
Young, M. D., Wakefield, M. J., Smyth, G. K. & Oshlack, A. Gene ontology analysis for RNA-seq: accounting for selection bias. Genome Biol. 11, R14 (2010).
pubmed: 20132535
pmcid: 2872874
doi: 10.1186/gb-2010-11-2-r14
Di Lorenzo, G. et al. Lysosomal proteome and secretome analysis identifies missorted enzymes and their non-degraded substrates in mucolipidosis III mouse cells. Mol. Cell. Proteom. 17, 1612–1626 (2018).
doi: 10.1074/mcp.RA118.000720
Saftig, P. et al. Mice deficient in lysosomal acid phosphatase develop lysosomal storage in the kidney and central nervous system. J. Biol. Chem. 272, 18628–18635 (1997).
pubmed: 9228031
doi: 10.1074/jbc.272.30.18628
Parfitt, A. M. et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Miner. Res. 2, 595–610 (1987).
pubmed: 3455637
doi: 10.1002/jbmr.5650020617